Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up (Q46135612)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 February 2009

Language	Label	Description	Also known as
English	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up	scientific article published on 3 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

diabetic macular edema

1 reference

based on heuristic

inferred from title

Jans Fromow-guerra

object named as

Jans Fromow-Guerra

3

0 references

author name string

J Fernando Arevalo

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Juan G Sanchez

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Lihteh Wu

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Maria H Berrocal

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Michel E Farah

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Jose Cardillo

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Francisco J Rodríguez

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Pan-American Collaborative Retina Study Group (PACORES)

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 February 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

Graefe's Archive for Clinical and Experimental Ophthalmology

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

247

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

735-743

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19189118

https://scigraph.springernature.com/pub.10.1007/s00417-008-1034-x

0 references

Diabetic maculopathy. A critical review highlighting diffuse macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00417-008-1034-X

21 January 2018

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

1 reference

https://api.crossref.org/works/10.1007%2FS00417-008-1034-X

21 January 2018

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

2 references

https://api.crossref.org/works/10.1007%2FS00417-008-1034-X

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

1 reference

https://api.crossref.org/works/10.1007%2FS00417-008-1034-X

21 January 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00417-008-1034-X

21 January 2018

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safe and effective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Macular edema. A complication of diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global and societal implications of the diabetes epidemic

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pathogenesis of edema in diabetic maculopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19189118

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00417-008-1034-X

1 reference

https://api.fatcat.wiki/v0/release/mtub3w3lljg43cixrrbcqmxh6y

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_mtub3w3lljg43cixrrbcqmxh6y

1 reference

https://api.fatcat.wiki/v0/release/mtub3w3lljg43cixrrbcqmxh6y

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/mtub3w3lljg43cixrrbcqmxh6y

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46135612&oldid=2094191471"